PSP001 - A First-in-disease human PEGIFN-λ Chimera
July 5th,2022 complet Phase 1 SAD cohorts; |
Date:2019-08-05 18:47:57 | Visits: |
Prev:May 3rd,2021 Phase 1 Site Initiation Visit; Next:Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection |